A5059348648- Cutaneous lymphoproliferative disorders research
- Autoimmune Bullous Skin Diseases
- Skin Diseases and Diabetes
- Cutaneous Melanoma Detection and Management
- Dermatology and Skin Diseases
- Nonmelanoma Skin Cancer Studies
- Oral Health Pathology and Treatment
- Nail Diseases and Treatments
- Genetic and rare skin diseases.
- Lymphoma Diagnosis and Treatment
- Cancer and Skin Lesions
- Autoimmune and Inflammatory Disorders
- Chemotherapy-related skin toxicity
- Dermatologic Treatments and Research
- Hidradenitis Suppurativa and Treatments
- Asthma and respiratory diseases
- Skin Protection and Aging
- Urticaria and Related Conditions
- Vascular Tumors and Angiosarcomas
- Fungal Infections and Studies
- Allergic Rhinitis and Sensitization
- Hair Growth and Disorders
- Tattoo and Body Piercing Complications
- Psoriasis: Treatment and Pathogenesis
- Sympathectomy and Hyperhidrosis Treatments
University of Campania "Luigi Vanvitelli"
2016-2025
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
2017-2025
Instituto de Investigación Biosanitaria de Granada
2022
Nepal Medical College Teaching Hospital
2022
Baylor College of Medicine
2022
University of Naples Federico II
2011-2020
University of Milan
2019
Istituto Nazionale di Fisica Nucleare, Sezione di Napoli
2014
University of Padua
2007
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles.The course unpredictable and current available treatments have variable efficacy.Nowadays, there relatively little evidence on treatment of AA from well-designed clinical trials.Moreover, none the or devices commonly used to treat are specifically approved by Food Drug Administration.The italian Study Group for Cutaneous annexial disease Society dermatology proposes these guidelines diagnosis
Abstract Background Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) face and scalp. Methods We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate efficacy tolerability tirbanibulin real‐life setting. 250 patients were enrolled. Tirbanibulin, ointment, was applied daily five consecutive days. The measured with modifications Actinic Keratosis Area Severity Index (AKASI). A satisfactory...
Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options AD have recently undergone revolutionary change by the introduction of first biologic drug. Availability in daily practice last version international guidelines, taking peculiarities country into account, can contribute to good clinical Italy. To adapt European Dermatology Forum (EDF) guidelines Italian medical–legal context, EDF were assessed independently two independent renowned experts field...
Additional data supporting the findings of this manuscript are available on reasonable request to corresponding author.
Introduction: Managing rubbing injuries in atopic dermatitis is challenging and has a significant impact on patients' quality of life. Polyhexamethylene biguanide (PHMB) Rigenase® (a patented Triticum vulgare extract) show promise tissue repair antimicrobial activity. Objective: The aim this study was to compare the effectiveness two topical treatments, Fitostimoline® Plus spray hydrating formulation with hyaluronic acid, secondary dermatitis. Materials Methods: This comparative enrolled 68...
Introduction: Pustular psoriasis (PP) is a rare life-threatening skin disease with negatively impact on quality of life (QoL). Clinically, it may be systemic (generalized pustular [GPP]) or localized palms and soles (palmoplantar pustulosis [PPP]). It not to observe plaque associated GPP. Objective: We explored the therapies used for PP their correlation patient QoL scores, through cross-sectional study using retrospective data from monocentric database in period 2017-2021. Method: Patient...
Mogamulizumab is a humanized monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity that targets chemokine receptor type. Several clinical trials and real-life experiences confirmed the efficacy safety profiles of mogamulizumab as second-line therapy beyond, biochemical- dermatology-specific quality life physical functioning, high treatment satisfaction. Systemic drugs are usually used in patients resistant or advanced forms cutaneous T-cell lymphomas (especially...
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterised by painful, necrotic ulcerations. PG described as rare disease: the world‐wide incidence estimated to be around 3 10 cases per million population year. These estimations are based mostly on case reports and retrospective series; there no prospective, multicentre studies matter. The apparent rarity of in contrast with our clinical perception dermatologists: opinion, not so uncommon. Therefore, we decide investigate...
Several types of B-cell lymphomas, including both primary cutaneous lymphomas and systemic may affect the skin, with partially overlapping clinical, morphological immunohistochemical features. Currently, World Health Organization (WHO) classification does not include diffuse large (DLBCL) considers leg-type DLBCL only DLBCL. Here we report case a 72-year-old white woman neoplasm comprised cells round nuclei, irregularly clumped chromatin one or more inconspicuous nucleoli. The...
Alopecia areata (AA) is a complex immune‐mediated disorder, which difficult to treat. The available treatment options seem have limited benefit, help only some patients and high relapse rate. We evaluated new therapeutic option for moderate severe AA based on the combination of photodynamic therapy (PDT) with 5‐aminolaevulinic acid (ALA) microneedling (MN). In total, 14 were enrolled, these randomly divided into 3 groups: Group A (MN alone; n = 9), B (ALA‐PDT 15) C (combination MN ALA‐PDT;...
Background: Guselkumab is the first approved human IgG1λ monoclonal antibody selectively targeting p19 subunit of IL23. Its effectiveness and safety were widely reported by clinical trials. However, these results must be confirmed in real life since its deals with more complicated subjects respect to Currently, real-life data on use guselkumab following treatment failure ustekinumab are limited, existing studies usually show a small cohort and/or reduced follow-up period. In this context,...